InvestorsHub Logo
Followers 469
Posts 23399
Boards Moderated 0
Alias Born 02/05/2004

Re: newflow post# 124803

Friday, 05/20/2016 9:11:17 PM

Friday, May 20, 2016 9:11:17 PM

Post# of 130502
they can sell low and then lower - it doesn't matter

they still make their strike prices regardless of where the share price trades

why do you think they call it death spiral financing

and if the volume diminishes, they'll put a pump & dump together

and you'll get 2 or 3 days worth of activity

separated by months of more conversions, RS's and AS increases

AMBS's business model failed gloriously

they have failed to license anything noteworthy

they have failed to get CLIA for their AMDX products

they have no AFIRM grant funding to run ESS test trials with

no $7.45-Mil. Grow NJ Assistance Tax Credit on the DioGenix deal

they have no near term assets that can produce any kind of revenue

Eltopra Ph 2 studies will require more testing

MANF is light years away from any revenue whatsoever

SeraPro, NuroPro, PhenoGuard, Georgetown Assays can't generate revenue

and they went out on a $40-Mil. reckless sending spree on credit

and didn't buy anything that was revenue producing whatsoever

bottom line - their broke

and have now been taken to the cleaners by the toxic lenders

and as a result, lost majority control of the company

Gerald hyped the company for years

and now his name along with the company's is permanently corrosive

sad but true...



AJMHO